%0 Journal Article %A Miao, Congrong %A Radu, Gertrud U. %A Caidi, Hayat %A Tripp, Ralph A. %A Anderson, Larry J. %A Haynes, Lia M. %T Treatment with respiratory syncytial virus G glycoprotein monoclonal antibody or F(ab′)2 components mediates reduced pulmonary inflammation in mice %D 2009 %J Journal of General Virology, %V 90 %N 5 %P 1119-1123 %@ 1465-2099 %R https://doi.org/10.1099/vir.0.009308-0 %I Microbiology Society, %X Therapeutic treatment with a non-neutralizing monoclonal antibody (mAb) (131-2G) specific to respiratory syncytial virus (RSV) G glycoprotein mediates virus clearance and decreases leukocyte trafficking and interferon gamma (IFN-γ) production in the lungs of RSV-infected mice. Its F(ab′)2 component only mediates decreased leukocyte trafficking and IFN-γ production without reducing virus replication. Thus, this mAb has two independent actions that could facilitate treatment and/or prevention of RSV infection by reducing both virus replication and virus-induced pulmonary inflammation. %U https://www.microbiologyresearch.org/content/journal/jgv/10.1099/vir.0.009308-0